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Abstract. The T cell receptor (TCR) consists of the 
Tiot[3 heterodimer and the associated CD378E and ge 
chains. The structural relationships between the sub- 
units of the TCR complex are still not fully known. In 
this study we examined the role of the extracellular 
(EC), transmembrane (TM), and cytoplasmic (CY) do- 
main of CD37 in assembly and cell surface expression 
of the complete TCR in human T cells. A computer 
model indicated that the EC domain of CD37 folds as 
an Ig domain. Based on this model and on alignment 
studies, two potential interaction sites were predicted in 
the EC domain of CD3~/. Site-directed mutagenesis 
demonstrated that these sites play a crucial role in TCR 
assembly probably by binding to CD3e. Mutagenesis of 
N-linked glycosylation sites showed that glycosylation 
of CD3~ is not required for TCR assembly and expres- 
sion. In contrast, treatment of T cells with tunicamycin 
suggested that N-linked glycosylation of CD38 is re- 
quired for TCR assembly. Site-directed mutagenesis of 
the acidic amino acid in the TM domain of CD3~/dem- 
onstrated that this residue is involved in TCR assembly 
probably by binding to Ti13. Deletion of the entire CY 
domain of CD3~/did not prevent assembly and expres- 
sion of the TCR. In conclusion, this study demonstrated 
that specific TCR interaction sites exist in both the EC 
and TM domain of CD3% Furthermore, the study indi- 
cated that, in contrast to CD3q¢, glycosylation of CD38 
is required for TCR assembly and expression. 
T 
HE T  cell receptor (TCR) 1 consists of the disulfide 
linked Tiot13 heterodimer and the non-covalently as- 
sociated CD3~/8~ and 42 chains. The function of the 
Tia13 dimer is to recognize antigen presented on major his- 
tocompatibility complex encoded class I or class II mole- 
cules on the surface of antigen presenting cells (15,  49), 
whereas the major role of the CD3 and the 4 chains is to 
mediate activation signals and to regulate the level of TCR 
expression (16, 38, 57). All of the TCR chains are type I in- 
tegral membrane proteins  (12,  30,  50).  Except for 4 the 
TCR chains belong to the immunoglobulin (Ig) superfam- 
ily (10, 22, 35, 60). 
All the TCR chains are required for efficient TCR ex- 
pression at the cell surface (8), but despite extensive re- 
search the subunit interactions within the TCR are still not 
fully understood. Several studies have described the pres- 
ence of intracellular CD38e, ~/e, 44, and Tiot13 dimers (2, 4, 
43)  and  these  dimers can  form  independently of other 
TCR chains. Transfection of TCR chains into COS cells 
has demonstrated a preferential binding of Tia to CD38e 
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dimers (2) and cross-linking experiments have shown that 
Ti[3 is in close contact to CD3~ and to a lesser extent to 
CD3e at the surface of T cells (6, 31, 52). From these re- 
suits a  TCR model has been proposed in which CD38~ 
dimers  associate with Tic~ and  CD3~  dimers  associate 
with Ti13 (41). It is presently thought that 42 associates with 
this putative hexameric partial TCR complex via a  com- 
pound determinant created by the complex. The specific 
chains that interact with 42 are not known although experi- 
ments have indicated that Tia and 13 are involved (20, 21). 
Recent experiments have indicated that the extracellu- 
lar (EC) domains of the TCR chains are involved in as- 
sembly of the TCR. One study demonstrated that the asso- 
ciation of CD3 chains with Ti13 was stabilized by the EC 
constant (C) domain of the Ti13 chain (59).  In another ex- 
periment it was shown that the assembly of Tia and Ti13 
was dependent on the EC domains of these chains (41). 
Both experiments involved the use of COS cells. As differ- 
ent conditions for TCR assembly might exist in non-T cells 
compared with T cells, conclusions on TCR assembly based 
on results obtained with non-T cells should be drawn with 
caution. We have recently demonstrated that the EC do- 
main of CD38  can not substitute for the EC domain of 
CD3-y in assembly of the complete TCR in T  cells (58). 
This indicates that the EC domain of CD3~/has a specific 
role in TCR assembly and expression. 
The  CD3"y chain contains two N-linked glycosylation 
sites in the EC domain. The general role of protein glyco- 
sylation is still not fully understood. However, experiments 
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lizing the structure of proteins, in modifying the functional 
activity of proteins,  in  recognition events,  and in  signal 
transduction  after  ligand-receptor  binding  (reviewed  in 
reference 53).  In  addition,  it has  recently been demon- 
strated that mutation of a glycosylation site in the transfer- 
rin receptor has a profound negative effect on the appear- 
ance of the receptor on the cell surface (61). The role of 
CD3~/  glycosylation in  assembly,  intracellular  transport 
and expression of the TCR is unknown. 
Each of the TCR chains contains one or two charged 
amino acids in their transmembrane  (TM) domain.  Sev- 
eral  studies  have  demonstrated  a  requirement  of these 
charged amino acids for complete TCR assembly. Muta- 
tion of both the TM basic amino acids in Tict  abolished 
TCR expression in T  cells (3, 26). Furthermore, in COS 
cells  the  association  of Tit~ with  CD3~  was  impaired  if 
both the TM basic amino acids in TioL  were changed to Leu 
or if the TM acidic amino acid in CD3~ was changed to 
Leu (42). Point mutation of the Til~ TM basic amino acid 
also abolished TCR expression in T cells due to the inabil- 
ity of the mutated Til3 chain to associate with the  CD3 
chains (1). In agreement with this, it has been shown in 
COS cells that if the charged amino acid in the TM domain 
of any of the CD3 chains was changed to a hydrophobic 
amino acid the association between CD3 and the Ti chains 
was  abolished, whereas the CD3-CD3  associations were 
not dependent on the presence of these charged amino ac- 
ids (23). These experiments indicate that the charged TM 
amino acids of the TCR subunits play an import role in the 
interaction between Ti and CD3 chains. However, the role 
of the charged amino acid in the TM domain of CD37 in 
assembly of the complete TCR has not been studied in T 
cells. Furthermore, the role of the cytoplasmic tail of CD3~ 
in TCR assembly and surface expression is unknown. 
On the basis of a computer model and alignment studies 
we identified sites in the EC domain of CD3~/that could 
be involved in  interactions with  other TCR  chains.  The 
role of these sites in TCR assembly was subsequently ana- 
lyzed  by  transfecting  site-directed  mutagenized  CD3~/ 
cDNA into the  CD3~/ negative T  cell variant JGN  (18). 
Furthermore, the role of N-linked glycosylation of the EC 
domain, the role of the charged residue in the TM domain, 
and the role of the cytoplasmic (CY) domain of CD3~ for 
TCR assembly and expression was studied. 
Materials and Methods 
Computer Model Building 
The  model  of CD3~,  was  built  using software  programs from Biosym 
Technologies (San Diego, CA). The initial model was built using Homol- 
ogy  ® and three structures (44, 48, 55)  all containing the Ig superfamily 
fold. The resulting structure was energy minimized using the Discover  ® 
program and the CFF91  forcefield and molecular dynamics were subse- 
quently  performed.  The  final  structure  was  analyzed  using  program 
PROCHECK (37), and the secondary structural elements were identified 
based on the Kabsh-Sander algorithm (27). 
Cells and Medium 
JGN cells, a TCR cell surface negative variant of the human T  cell line 
Jurkat that synthesize no CD3~ (18), and the original Jurkat cell line, J76, 
were cultured in RPMI 1640 medium (GIBCO BRL, Paisley, UK) supple- 
mented with penicillin, 0.5 IU/I (Leo, Ballerup, Denmark), streptomycin, 
500 mg/1 (Novo, Bagsvoerd, Denmark), and 10% (vol/vol) FCS (Sera-Lab 
Ltd., Sussex, UK) at 37°C in 5%  COz. The Ti[~ deficient Jurkat variant 
JBN (49) was kindly provided by Dr. R. N. Germain (Bethesda, MD). 
Antibodies and Chemicals 
The UCHT1 mouse mAb directed against human CD3e was obtained pu- 
rified and phycoerythrin (PE) conjugated from Dakopatts A/S (Glostrup, 
Denmark).  F101.01  mouse mAb  against  a  conformational epitope  on 
CD3-/~ and CD38e dimers in association with the Ti chains was produced 
in our own laboratory (19). HMT-3.2 hamster mAb against an epitope on 
the IC domain of human CD3"y and mouse CD3~,  and ~ was kindly do- 
nated by Dr. Ralph Kubo (Cytel Corporation, San Diego, CA). 
Constructs and Generation of Stably Transfected Cells 
All mutations and truncations were constructed as previously described 
(16,  18, 57)  by the polymerase chain reaction (PCR)  using Vent DNA 
polymerase containing 3'-->5' proofreading exonuclease activity (New En- 
gland Biolabs, Inc., Beverly, MA) and the wild-type human CD3-/cDNA 
containing ptasmid pJ6T3~/-2  (33)  as template.  PCR  products were cut 
with XbaI-Ncol,  cloned into the 4.1-kb XbaI-NcoI fragment of pBlue- 
script-13WT  (18) and confirmed by complete DNA sequencing. The 1.8-kb 
XbaI-BamH! pBluescript fragment containing the PCR product was sub- 
sequently cloned into the 5.9-kb XbaI-BamHI fragment of the expression 
vector pTI3Fneo (45).  Transfections were performed using the Bio-Rad 
Gene Pulser at a setting of 270 V and 960/~F with 40 l~g of plasmid per 
2  x  107 cells. After electroporation, cells were maintained in RPMI me- 
dium for 24 h and plated at 1 x  104 and 5 ×  104 cells/ml in 96-well tissue 
culture plates (Greiner GmbH, Frickenhausen, Germany) in medium con- 
taining 1 mg/ml G418 sulphate (Geneticin) (GIBCO BRL). After 3-4 wk 
of selection, G418 resistant clones were expanded and maintained in me- 
dium without G418. 
Flow Cytometric Analysis 
Cells were washed twice in ice cold PBS, 0.02% wt/vol NAN3, 1% vol/vol 
FCS, incubated with PE conjugated mAb for 25 min at 4°C, and washed 
twice in ice cold PBS. Flow cytometric analysis was performed on a FAC- 
Scan flow cytometer (Becton Dickinson, Mountain View, CA). Live ceils 
were gated using forward and side scatter and 10,000 cells were analyzed 
in each sample. 
Biosynthetic Labeling, Solubilization, 
Immunoprecipitation, and Electrophoresis 
For metabolic labeling studies, cells were washed twice in PBS and resus- 
pended at 5 x  106 cells/ml RPMI 1640 without methionine at 37°C for 30 
min. After starvation, cells were washed once, resuspended at 5  x  107 
cells/ml RPMI 1640 without methionine, and incubated for the period in- 
dicated with 500 t~Ci/ml  [35S]methionine (Amersham Laboratories, Am- 
ersham, UK). In pulse-chase experiments cells were pulsed for 30 min at 
37°C and chased in complete medium for the indicated periods. Cells were 
washed three times in cold PBS, and solubilized for 30 min at 4°C in lysis 
buffer (20 mM Tris-HCl, pH 8.0,  1 mM MgCl2,  150 mM NaCl,  1 mM 
PMSF, 8 mM iodoacetamide, and 1% digitonin (Sigma Chemical Co., St. 
Louis, MO). The supernatant obtained after centrifugation for 5 min at 
1500  g  was  precleared  by  incubation with  protein  A-Sepharose  (PA) 
(Pharmacia LKB Biotechnology, Uppsala, Sweden). For immunoprecipi- 
tation, precleared lysate was incubated with 1.0 I-~g of mAb for 2 h at 4°C. 
PA was added and the incubation continued for 2 h. The immunoprecipi- 
tates were washed five times in lysis buffer, boiled for 5 min with sample 
buffer (50  mM Tris-HCl, pH 6.8,  2%  SDS,  10%  glycerol, 0.01%  bro- 
mophenol), and subjected to SDS-PAGE on 12% acrylamide gels. Auto- 
radiography of dried gels was performed by using Hyperfilm-MP (Amer- 
sham). 14C-labeled  proteins from Amersham were used as molecular mass 
markers. 
Cell Surface Iodination 
Cells were surface iodinated as previously described (19) and soluhilized 
for 45 min at 4°C in lysis buffer. Immunoprecipitation, electrophoresis, 
and autoradiography were performed as described above. 
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For deglycosylation studies, cells were surface iodinated,  solubilized, and 
immunoprecipitated  as described.  The immunoprecipitates  were boiled 
for 5 min in elution buffer (0.5% SDS, 20 mM Tris-HC1, pH 8.0). The elu- 
ate was divided in two parts and treated with either 10 U/ml of N-glyca- 
nase (Genzyme, Cambridge, MA) or left untreated. After incubation  for 
18 h at 37°C the eluates  were boiled for 5 min in 2×  sample buffer and 
subjected to SDS-PAGE on 12% acrylamide gels. 
Tunicamycin Treatment 
Cells were biosynthetically labeled as described above in the presence or 
absence  of 1 p~g/ml tunicamycin (Boehringer  Mannheim, Vedboek, Den- 
mark). 
Results 
Prediction of Potential Interaction Sites 
in the Extracelluiar Domain of CD3 y from a 
Computer Model 
The EC domain of CD3~/has been suggested to fold as an 
Ig domain since the residues that are considered to be a 
hallmark of Ig related sequences are present in the CD3~/ 
EC domain (35, 60). The strategy used to identify poten- 
tial interaction sites in  the EC domain of CD37  was  to 
search for conserved CD37-specific regions that were not 
shared with other members of the Ig superfamily since a 
potential interaction site  should  not include  structurally 
important amino acids. By alignment of CD37 from hu- 
man, mouse, rat, and sheep two conserved regions namely 
amino acid 17-21 and 57-60 were identified (Fig. 1 A) and 
(39). The 17-21 and 57-60 regions are not generally shared 
between CD3~/and other members of the Ig supeffamily 
except CD3~ in which the 57-60 site, in particular, shows a 
high degree of conservation (Fig.  1 A  and reference 35, 
60).  The 57-60 region was  conserved even in  the  avian 
CD3 Tl1.15 chain except from a Lys to Asp substitution at 
position 57  (Fig.  1 A).  The mere  conservation of these 
CD3"~(~) regions between species suggests that they serve 
an important functional or structural role. However, since 
these regions are not conserved among other members of 
the Ig superfamily it is unlikely that they serve a structural 
role e.g., in stabilizing the native conformation of the as- 
sumed EC Ig domain of CD3~/. To examine whether the 
17-21 and 57-60 regions could constitute possible interac- 
tion sites a computer model of the EC domain of CD3~t 
was built. According to the computer model, the EC do- 
main of CD3-y folds as an Ig C domain. A secondary struc- 
ture prediction according to the Kabcsh-Sander algorithm 
(27), based on the 4, and + angles and hydrogen bonding 
pattern of the residues in the computer model, confirms 
two anti-parallel [~-sheets characteristic of an Ig C domain. 
One 13-sheet contains three anti-parallel 13-strands  (C, F, 
and G) whereas the other contains four such strands (A, B, 
E, and D) (Fig. 2 A). Fig. 1 A  shows the position of these 
strands  in  the  primary  sequence  of  CD3,/.  Secondary 
structural elements, such as the anti-parallel 13-sheets of an 
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Figure 1.  Primary and secondary structure analysis of CD37.  (A) Alignment of the EC domains of CD3~/  and CD3~  from human, 
mouse, rat, and sheep compared to avian CD3. Glycosylation sites are underlined. Boxes denote the two initially identified interaction 
sites. The position of the f3-strands according to the computer model are shown. (B) Ramachandran plot of the EC domain of CD3~,. 
Only residues that according to the computer model are part of the B-strands are shown. Gly residues are omitted. (C) Kyte-Doolittle 
plot of the EC domain of CD3~. The 17 and 56 sites are shown in grey boxes. 
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of the extracellular  domain of 
CD3-y. (A) The EC domain of 
CD3~.  Loops  are  colored  in 
yellow with the 17-21 and 57- 
60 regions  colored in red and 
blue,  respectively.  The arrows 
(green) show the 13-strands ac- 
cording  to  the  Kabsh-Sander 
algorithm  (27). (B) Space fill- 
ing model of the EC domain of 
CD3~/seen from the 16-21 and 
56--60 regions.  Loops are col- 
ored in yellow, strands are col- 
ored in green and the two re- 
gions  16-21 and 56-60  in  red 
and blue, respectively. 
Ig domain, impose restrictions upon the qb and ~ angles of 
its residues (54) unless the residue is a Gly that is less re- 
stricted.  A  Ramachandran  plot  of  the  computer  model 
(Fig. 1 B) showed that the residues, which according to the 
model were part of the B-strands, did in fact exhibit qb and 
angles  that  were  within  the  restricted  anti-parallel 
B-strand area. The Gly residues were omitted in this plot. 
According to the secondary structure prediction based 
on the Kabcsh-Sander algorithm (27) the 17-21 region and 
the majority of the 57-60 region was found in loops (Figs. 
1 A  and 2). Since loops only have a minor role in maintain- 
ing the structure of a protein, this supported the idea that 
the 17-21  and 57-60 regions did not serve as structurally 
important regions but could function as interaction sites. 
Protein-protein  interactions  usually  involve hydrophobic 
or hydrophilic contacts (25). In a Kyte-Doolittle plot (36) 
the 17-21 region was found to include part of the most hy- 
drophobic region of the EC domain of CD3",/as well as a 
hydrophilic region (Fig. 1 C). In the computer model the 
hydrophobic part of the 17-21 region was found to contain 
two exposed hydrophobic residues  (Val 20  and Leu 21). 
Glu 16 is conserved among human and sheep CD3~/and is 
exposed according to the computer model. We therefore 
included  Glu  16 in  the  hydrophilic part of the  first con- 
served region and selected the 16-21 region as a potential 
interaction site. This region was hereafter denoted the 17 
site (Fig. 3). 
The 57-60 region was in a Kyte-Doolittle plot (Fig. 1 C) 
found to constitute one of the most hydrophilic regions of 
the  EC  domain  of  CD3"v.  This  region  contains  three 
charged  residues  (Fig.  1 A).  These charged  amino  acids 
could be involved in salt bridges between CD3~  and an- 
other protein of the TCR. Alternatively they could merely 
interact with water or be involved in intra-molecular salt 
bridges.  However, since neither of these interactions  are 
major contributors  to the  stability of a  protein  (17)  this 
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Figure 3.  Overview of the transfectants. 
Truncation of the 
cytoplasmic  tail 
would probably not explain the conservation of these resi- 
dues among CD3~/chains from several species. The com- 
puter model showed that two of these charged residues 
were exposed (Asp 58 and Arg 60) (Fig. 2). Since Ala 56 is 
conserved among human, mouse, and rat CD3~/and was 
exposed according to the computer model, the 56-60  re- 
gion  was  selected  as  another  potential interaction site. 
Hereafter this region was denoted the 56 site (Fig. 3). 
Role of the 17 and 56 Sites in TCR Assembly 
and Expression 
The production of the CD3~/negative T cell variant JGN 
(18) allowed us to study the consequences of various mu- 
tated CD3~/chains in TCR assembly and expression. JGN 
cells do not express the TCR at the cell surface but upon 
transfection of cDNA encoding wild-type CD3~/into JGN 
cells they become TCR cell surface positive (Fig. 4 A). To 
examine whether the 17 and 56 sites constituted interac- 
tion sites, the amino acids 16-21 and 56-60 were replaced 
with Gly by site-directed mutagenesis in two separate con- 
structs, CD3~/-17 and 56 (Fig. 3). Gly was selected because 
it is expected to adopt the conformation required for the 
stability of the secondary structure due to its flexibility 
with respect to the +  and ~J angles (54).  Therefore, Gly 
should not add any strain on the structure. Furthermore, 
according to the computer model both the 17 and 56 sites 
,A  ,B 
JGNy-WT 
A 
/  \ 
0  4 
JGNy-  17 
~0  4 
C 
JGN¥-56 
*D  *E  °~" 
JGNy-N30Q 
/  i 
d"  %,~', 
04 
JGNy-N70Q  r0Q 
JGNy-E100Q 
*H  *I 
JGNy-E100L  ,tJ  JGNy-E  100K  JGNy-Q  117 
2 
Figure 4.  Cell surface expression of the TCR. The parental and transfected JGN ceils were stained with anti-CD3e mAb (UCHT1) di- 
rectly conjugated with PE and subsequently  analyzed by flow cytometry. The abscissa represents the fluorescence on a logarithmic scale 
and the ordinate the relative cell number on a linear scale. The fluorescence histogram of each transfected cell line (filled histograms) is 
compared to the fluorescence histogram of the parental JGN cell line (open histograms). The analyzed cell line is indicated in each his- 
togram: JGN2,-WT (A), JGN~/-17 (B), JGN',t-56 (C), JGN%,-N30Q (D), JGN.,/-N70Q (E), JGN-,,,-N30/70Q (F), JGN.,/-E100Q (G), JGNT- 
E100L (H), JGNT-E100K (/), and JGNT-Qll7 (J). 
Dietrich et al. Structure and Role of CD3? in TCR Assembly  303 Figure 5.  Metabolic labeling 
and  immunoprecipitation. 
JGN-/-WT (lanes 1-3 and 10- 
12),  JGN3,-I7  (lanes  4--6), 
JGN (lanes  7-9)  and JGN-y- 
56  (lanes  13-15)  cells  were 
metabolically  labeled  for 30 
min, lysed in 1% digitonin ly- 
sis  buffer,  and  immunopre- 
cipitated  with  either  anti- 
CD3~/(lanes 1, 4, 7, 10, and 
13), anti-CD3c  (lanes 2, 5, 8, 
11, and 14) or F101.01 mAb 
(lanes  3,  6,  9,  12,  and  15). 
Samples  were  analyzed  by 
SDS-PAGE  under  nonre- 
ducing  conditions  on a  12% 
polyacrylamide gel. The posi- 
tions  of the TCR chains  are 
indicated  (fg,  fully  glycosy- 
lated;  pg,  partially  glycosy- 
lated). 
constituted loops and loops seem to prefer Gly due to the 
conformational requirements of the amino acids in a loop 
region (11). In addition, with respect to the functional con- 
sequence of the substitution, we expected that Gly would 
only make a minor contribution to an interaction, whether 
this was hydrophilic or hydrophobic, due to its lack of side 
chain. 
The CD3~-WT, -17,  and -56 constructs were separately 
transfected into JGN cells. Stable clones were selected in 
medium containing G418 and 30 clones from each of the 
transfection  experiments were subsequently screened for 
TCR  surface  expression  by  FACS  analysis.  23  of  the 
JGN'y-WT clones expressed the  TCR at the  cell surface 
whereas  none  of  the  JGN'y-17  or  JGN-y-56  clones  ex- 
pressed the TCR (Fig. 4, A-C). To analyze whether CD3~/ 
was  synthesized  in  the  transfectants,  JGN,  JGN',/-WT, 
JGN'y-17, and JGN',/-56 cells were metabolically labeled, 
solubilized in lysis buffer containing 1% digitonin, and im- 
munoprecipitated with anti-CD3% anti-CD3e, or F101.01 
mAb that only recognizes CD3~/~ or CD3g~ dimers in as- 
sociation with the Ti chains  (19).  All of the transfectants 
synthesized a protein at the size of the CD3"y chain (Fig. 5, 
lanes 1, 4, 10, and 13) demonstrating that the lack of TCR 
cell surface expression in JGN~/-17 and JGN~/-56 cells was 
not due to a lack of the CD3~ chain. In JGN~/-WT cells the 
anti-CD3~ mAb clearly coprecipitated CD33, in contrast to 
JGN'v-17 and JGN~-56 cells in which CD3-/did not copre- 
cipitate with CD3e (Fig. 5, lanes 2, 5, 11, and 14). Immuno- 
precipitation with F101.01  demonstrated that both CD3",/E 
and  CD3ge  dimers  associated  with  the  Tial3  chains  in 
JGN',/-WT cells (Fig. 5,  lanes 3  and 12).  In contrast, only 
CD3ge dimers were found associated with the Tia[3 chains 
in  JGN',/-17 and  JGN-/-56 cells  (Fig.  5,  lanes 6  and  15). 
These results demonstrated that mutation of the 17 and 56 
sites had  a  pronounced  effect on TCR assembly and ex- 
pression. The formation of CD3"ye dimers was markedly 
decreased  in  JGN~/-17  and  -56  cells  as  compared  with 
JGN~,-WT and the association between CD3~/and the Tial3 
dimer seemed to be reduced, especially in JGN~/-56 cells. 
The band with a molecular mass of ~27 kD that was pre- 
cipitated with the anti-CD3-/mAb (Figs. 5 and 9) was also 
seen in the CD3~/negative cell line, JGN, (Fig. 5, lane 7) 
and was therefore regarded as a  protein unrelated to the 
TCR components. 
Role of N-linked Glycosylation  in TCR Assembly 
and Expression 
The role  of N-linked glycosylation of the  TCR chains  is 
unknown. The EC domain of CD3~ contains two sites for 
N-linked glycosylation, Asn  30  (N30)  and  Asn 70  (N70) 
(Fig. 1 A). To examine the role of CD3~/glycosylation in 
TCR assembly and expression three different CD3~ con- 
structs were made by site-directed mutagenesis. In CD3~/- 
N30Q Gin substituted for Asn 30, in CD3",/-N70Q Gln sub- 
stituted for Asn 70, and in CD3~-N30/70Q Gin substituted 
for both Asn 30 and 70 (Fig. 3). Gln was selected to substi- 
tute for Asn because Gln both physically and chemically is 
similar to Asn and Gln is often seen exchanged with Asn 
in homologous proteins (14). Therefore, the consequences 
of the mutations should only be due to the lack of glycosy- 
lation.  The  constructs  were  separately  transfected  into 
JGN cells. Stable clones were selected in medium contain- 
ing G418 and several clones from each transfection experi- 
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nicamycin.  J76  cells  were 
metabolically  labeled  in  the 
absence (-) or presence (+) 
of tunicamycin. Subsequently, 
the cells were lysed in digito- 
nin lysis buffer and immuno- 
precipitated  using  an  anti- 
CD3e  antibody.  Samples 
were analyzed under nonre- 
ducing  conditions  by  SDS- 
PAGE on a 12% acrylamide 
gel. The positions of the TCR 
chains are indicated  (fg, fully 
glycosylated;  pg,  partially 
glycosylated;  d,  deglycosy- 
lated [non-glycosylated]). 
Figure 6.  Cell surface labeling. J76 (lanes 1 and 6), JGN~/-N30Q 
(lanes  2  and  7), JGN~/-N70Q (lanes  3  and 8), JGN~,-N30/70Q 
(lanes  4  and  9)  and  JGN~-Qll7  (lanes  5  and  10)  cells  were 
surface iodinated,  solubilized in digitonin  lysis buffer and immu- 
noprecipitated with  anti-CD3~  mAb. Immunoprecipitates were 
either left untreated (lanes I-5) (-) or were treated with N-gly- 
canase (lanes 6-10) (+). Samples were analyzed  by SDS-PAGE 
under nonreducing  conditions  on a 12% polyacrylamide  gel. The 
positions  of the TCR chains are indicated  (fg, fully glycosylated; 
pg, partially glycosylated; dg, deglycosylated  [non-glycosylated]). 
ment were subsequently screened for TCR surface expres- 
sion by FACS analysis. As demonstrated in Fig. 4, D-F all 
of the constructs allowed TCR cell surface expression. To 
verify that the transfectants did express the TCR contain- 
ing  the  mutated  CD3~/  chains  at  the  cell  surface,  J76, 
JGN~/-N30Q, JGN~/-N70Q, and JGN~/-N30/70Q cells were 
surface iodinated, solubilized in lysis buffer containing 1% 
digitonin,  and immunoprecipitated with anti-CD3e mAb. 
The immunoprecipitates were either treated with N-glyca- 
nase or left untreated. J76 cells expressed the fully glycosy- 
lated  wild-type  CD3",/ with  a  relative  molecular mass of 
25-28 kD before treatment with N-glycanase and a  rela- 
tive molecular mass of 18 kD after N-glycanase treatment 
(Fig. 6, lanes 1 and 6). Interestingly, JGN~-N30Q cells ex- 
pressed  two forms of CD3-¢.  One  was  partially glycosy- 
lated  and  had  a  relative  molecular  mass  of  19-20  kD 
whereas the other was not glycosylated and had a molecu- 
lar mass of 18 kD (Fig. 6, lanes 2 and 7). JGN~/-NTOQ cells 
only expressed  the  partially  glycosylated form of CD3~ 
and JGN,/-N30/70Q  cells only expressed the nonglycosy- 
lated CD3"~ as expected (Fig. 6, lanes 3, 4, 8, and 9). 
To further  study the  role  of N-linked  glycosylation in 
the assembly of the TCR, J76 cells were preincubated with 
tunicamycin, metabolically labeled in the presence of tuni- 
camycin, solubilized in lysis buffer containing  1%  digito- 
nin, and subsequently immunoprecipitated with anti-CD3~ 
mAb.  Fig.  7  demonstrates  that  non-glycosylated  CD3"y 
and Till3 dimer coprecipitated with CD3e. However, the 
non-glycosylated CD38  chain  did  not  coprecipitate  with 
the rest of the complex. This indicated that in contrast to 
CD3% the glycosylation of CD38  (or another protein) is 
required in the assembly of CD38 and CD3~. 
To examine whether glycosylation of CD3-/ influences 
its stability in the ER, the JBN cell line, that contains all 
the TCR chains  except Ti[3, was transfected with CD3~- 
N30/70Q and stable clones were selected in medium con- 
taining G418.  The absence of Ti[3 ensured that the TCR 
chains  would  not  escape  the  ER  and  the  presence  of 
CD3~/-WT allowed comparison of the stability of the non- 
glycosylated, the fully glycosylated, and the partially gly- 
cosylated CD3"y chain. JBN-N30/70Q  cells were pulse la- 
beled for 30 min and chased for 0,  1, 2, 6, or 20 h  before 
solubilization in digitonin lysis buffer and immunoprecipi- 
tation. Even after a  20-h chase period both the fully and 
non-glycosylated CD3~/chains were seen (Fig. 8). This in- 
dicated that N-linked glycosylation did  not influence  the 
stability of the CD3~/.  The disappearance of the partially 
glycosylated CD3~/  chain could  indicate  an instability  of 
this chain, or could merely be due to complete glycosyla- 
Dietrich et al. Structure and Role of CD3y in TCR Assembly  305 Figure 8.  Pulse-chase  exper- 
iment.  JBN-N30/70Q were 
pulse-labeled  for 30 min  at 
37°C and chased for 0 h, 1 h, 
2 h, 6 h, or 20 h. After solubi- 
lization  in  1%  digitonin, 
immunoprecipitations  were 
performed  using  an  anti- 
CD3~/  antibody  (HMT3.2). 
]~he immunoprecipitates  were  analyzed  by SDS-PAGE under 
nonreducing conditions on a 12% polyacrylamide gel. The posi- 
tions of the TCR chains are indicated (fg, fully glycosylated; pg, 
partially glycosylated; d, deglycosylated [non-glycosylated]). 
tion  of this  chain.  The  observed  decrease  in  molecular 
mass of the fully glycosylated CD3~/chain during the chase 
period is probably due to oligosaccharide modifications in 
the ER (32). 
Role of the Transmembrane Charged Amino Acid in 
TCR Assembly and Expression 
To examine the role of the charged amino acid Glu (El00) 
in  the  TM  domain  of  CD3%  three  different constructs 
were made in which Gin, Leu, and Lys substituted for Glu, 
respectively (Fig. 3). The constructs were separately trans- 
fected into JGN cells. Stable clones were selected in me- 
dium  containing  G418  and  30  clones  from  each  of the 
transfection experiments were subsequently screened for 
TCR  surface  expression  by  FACS  analysis.  21  of  the 
JGN~-E100Q clones expressed the TCR at the cell surface 
whereas none of the JGN'y-E100L or JGN'y-E100K clones 
expressed the TCR  (Fig. 4,  G-/). To analyze whether a 
CD3~/chain was synthesized in the transfectants, JGN~/- 
WT,  JGN~/-E100Q,  JGN~/-E100L  or JGN~/-E100K  cells 
were metabolically labeled, solubilized in lysis buffer con- 
raining 1%  digitonin, and immunoprecipitated with anti- 
CD3%  anti-CD3•,  or F101.01  mAb.  All of the  transfec- 
rants  synthesized  a  protein  at  the  size  of the  wild-type 
CD3~/  chain,  except for JGN~/-E100K cells in which the 
mobility of the CD3~/-E100K chain seemed to be mark- 
edly influenced  by the  mutation  as  the  mutated  CD3~/ 
chain  comigrated with  the  CD3~  and  •  band  (data  not 
shown).  In  JGN~/-WT  and  JGN'y-E100Q  cells  the  anti- 
CD3~/mAb coprecipitated the Tiotl3 dimer, the single Til3 
and  a  chains,  the  42 dimer and the  CD3• chain  (Fig.  9, 
lanes I  and 2). In contrast, in JGN~/-E100L the anti-CD3~/ 
mAb did not coprecipitate the 42 dimer and the single Til3 
and et chains,  and only faint bands  of Tial3  dimer were 
seen as compared with JGN-/-WT and JGN-y-E100Q cells. 
Only the CD3e chain was coprecipitated as strongly with 
CD3"y in JGN~-E100L cells as in JGN~/-WT and JGN~/- 
E100Q cells (Fig. 9, lanes 1-3). The anti-CD3• mAb co- 
precipitated CD3~/with  similar efficiency from all three 
cell lines (Fig. 9, lanes 4-6). The F101.01 mAb precipitated 
both CD3~/•  and CD3~• dimers together with the rest of 
the TCR from JGN~-WT and JGN'y-E100Q cells but did 
not  precipitate  CD3~/•  dimers  from  JGN'y-E100L  cells 
(Fig. 9, lanes  7-9). In contrast to JGN~/-WT and JGN~/- 
E100Q cells the 42 dimer was not coprecipitated in JGN~/- 
E100L cells with any of the mAbs tested further support- 
ing the findings that the TCR was not properly assembled 
in  JGN~/-E100L  cells.  These  experiments  demonstrated 
Figure 9.  Metabolic  labeling  and immunoprecipitation.  JGN~/- 
WT (lanes 1, 4, and 7), JGN~/-E100Q (lanes 2, 5, and 8), and 
JGN-~-E100L (lanes 3, 6, and 9) cells were metabolically labeled 
for 90 min, lysed in digitonin lysis buffer, and then immunopre- 
cipitated using either anti-CD3~ (lanes 1-3), anti-CD3e (lanes 4-6), 
or F101.01 mAb  (lanes  7-9). Samples were analyzed  by SDS- 
PAGE under nonreducing  conditions on a 12% polyacrylamide 
gel. The positions of the TCR chains are indicated (fg, fully glyco- 
sylated; pg, partially glycosylated). 
that the chemical and physical properties of the TM Glu in 
CD3"y play an important role in TCR assembly and  ex- 
pression at the cell surface. 
Role of the Cytoplasmic Domain in TCR Assembly 
and Expression 
To examine the role of the CY domain of CD3~/in TCR 
assembly and expression the construct CD3~-Qll7 st°p was 
made, in which the entire C¥  tail of CD3~/ was deleted 
(Fig. 3). The construct was transfected into JGN cells, sta- 
ble clones were selected in medium containing G418 and 
subsequently  screened  for  TCR  surface  expression  by 
FACS analysis. As demonstrated in Fig. 4 J, truncation of 
the CY tail of CD3~/did not impair TCR expression. To 
verify that CD3~/-Qll7  st°p did express the TCR containing 
the tail-less CD3~/chain at the cell surface, cells were sur- 
face iodinated,  solubilized in  lysis buffer containing  1% 
digitonin,  and  then  immunoprecipitated with  anti-CD3• 
mAb.  The immunoprecipitates were either treated  with 
N-glycanase or left untreated. As demonstrated in Fig. 6, 
lanes 5 and 10, JGN~/-Qll7 cells did express the TCR con- 
taining the truncated CD3"y chain at the cell surface. 
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The ExtraceUular Domain 
Although the majority of studies describing interactions of 
the TCR subunits have concentrated on the charged amino 
acids in the TM domains (1, 3, 13, 23, 26, 42) a role of the 
EC C domains of Tic~ and 13 for complete assembly of the 
TCR in T  cells has been described (9, 21). These studies 
describe point  mutations  of conserved amino  acids  that 
caused conformational changes of the Ti C  domains and 
abolished correct TCR assembly and  expression (9, 21). 
Recently, other experiments have also indicated a role for 
the EC domain of the TCR chains in the assembly of the 
TCR complex (41, 59). Cotransfecting pairs of CD3 chains 
and chimeric Ti[3-IL2 receptor c~ chains into COS cells in- 
dicated that the association between CD3~/, 8, or ¢ and Ti[3 
was stabilized by the ECC domain of the Ti[3 chain (59). 
Another experiment demonstrated that assembly of Ti[3 
with Tier or CD3E involved the extracellular domains of 
these chains (41). However, it should be noted that these 
results were obtained by cotransfecting COS cells with dif- 
ferent TCR chains  and chimeric proteins. These experi- 
ments reflect the ability of isolated TCR chains to interact 
with each other and do not necessarily represent the inter- 
actions that take place in the fully assembled TCR in T 
cells. We have recently demonstrated that the EC domain 
of CD38 can not substitute for the EC domain of CD3~ in 
assembly of the complete TCR in T  cells (58). This indi- 
cated that the EC domain of CD3~ might have a role in 
TCR assembly and lead us to search for potential interac- 
tion sites in this domain. The search was made according 
to  the  following criteria:  (a)  the  site(s)  should  be  con- 
served among CD3~ chains but not among other members 
of the  Ig  superfamily since  general  conserved  residues 
most probably have a structural role; (b) the site(s) should 
include  a  hydrophilic/hydrophobic region  since  protein- 
protein interactions often involve hydrophilic/hydropho- 
bic contacts; (c) the site(s) should contain exposed hydro- 
philic/hydrophobic residues that could be directly involved 
in an interaction; and  (d) the site(s) should probably be 
found in  loop regions  since  such  regions  have  a  minor 
structural  role  but  could  have  an  important  functional 
role. Based on alignment studies (Fig. 1 A  and reference 
39), a Kyte-Doolittle plot (Fig. 1 C) and a computer model 
of the extracellular domain of CD3~ (Fig. 2) two sites were 
found to fulfill these criteria, namely the  17 and 56 site. 
The present study demonstrated that both sites were re- 
quired for proper TCR assembly and cell surface expres- 
sion. The mutagenized CD3~/(CD3"y-17 or -56) associated 
weakly, if at all, with CD3¢ and binding to the Tia[3 dimer 
seemed to be reduced. In contrast, the association to the 
single Ti[3 seemed to be preserved. It is interesting that 
both the 17 and 56 site mutations seemed to have almost 
identical  effects on  TCR  assembly.  This  indicated  that 
both sites could be part of the same binding site to CD3¢. 
According to the computer model this is plausible as the 
17 and 56 sites are in close contact to each other (Fig. 2 B). 
A  more detailed analysis involving single point mutations 
is required to precisely define the binding site to CD3~. 
We can not exclude the possibility that the mutations af- 
fected  the  general  conformation  of the  EC  domain  of 
CD3~ that might be supported by the observation that the 
partially glycosylated form  of CD3~/ was  not  as  clearly 
seen in JGN~/-17 and JGN~/-56 cells as in JGN~/-WT cells. 
However, we can conclude that the EC domain of CD3",/is 
involved  in  TCR  assembly.  The  preserved  binding  be- 
tween the mutated CD3~ in JGN'y-17 or -56 cells and the 
single  Ti[3 indicated  that  pair-wise  interactions  between 
CD3~ and Ti[3 is not dependent on the 17 and 56 sites. In 
contrast, the association of CD3",/with CD3~ seems to re- 
quire the 17 and 56 sites. Both the 17 and 56 sites are par- 
tially  conserved between  CD3~/  and  CD38  chains  from 
human, mouse, rat, and sheep. Therefore, it could be spec- 
ulated that these sites serve similar functions in CD3-y and 
CD38. Experiments have shown that CD3~  and CD38~ 
dimers can be formed independently of other TCR chains 
(4, 18) and that CD3~/and CD38 compete for the binding 
to CD3e (18). This suggests that CD3~/and 8 each contain 
a  binding site to CD3e and furthermore share a  binding 
site on CD3~. The binding site to CD3~ could be the 17 
and 56 sites in both CD3-y and CD38. 
Oligosaccharides modify the local structure and overall 
dynamics of the proteins to which they are attached. They 
may alter the functional activity of a protein, they may be 
involved in molecular recognition events, and they may be 
involved in signal transduction (reviewed in reference 53). 
Recently a role of oligosaccharides in TCR assembly has 
been described. Persistence of glucose residues on N-linked 
oligosaccharides disrupted the associations of the chaper- 
one calnexin with both the Tic~ and [3, and furthermore re- 
stricted the ability of the Tic~ and [3 to form heterodimers 
(28). In this study we demonstrated that N-linked glycosy- 
lation of CD3-,/is not required for TCR assembly and ex- 
pression.  By  combining  the  results  from  the  computer 
model and the alignment of human, mouse, rat, and sheep 
CD3"y we found that the N-glycosylation sites in all species 
were located in other regions of CD3~ than the putative 
interaction sites 17 and 56. Furthermore, the CD3",/N-gly- 
cosylation sites were not conserved with respect to their 
position. This lack of conservation suggested that the N-gly- 
cosylation of CD3-,/is not involved in intermolecular inter- 
actions between the TCR subunits. In addition, since the 
non-glycosylated CD3~/chain was able to function in TCR 
assembly and expression, this indicated that glycosylation 
did not have a significant influence on the native confor- 
mation  of CD3~/. The  glycosylation of the  TCR  chains 
could, apart from TCR assembly (28), be involved in mo- 
lecular recognition events at the cell surface of T cells and/ 
or in signal transduction. Another potential role for glyco- 
sylation could be in the degradation of TCR chains in the 
ER (5). However, our experiments indicated that the sta- 
bility of CD3"y in the ER was not affected by glycosylation. 
It is interesting that JGN~-N30Q cells in addition to the 
partially glycosylated CD3~/also expressed the non-glyco- 
sylated CD3"y chain at the cell surface. This suggested that 
the efficient glycosylation of Ash 70 to some extent is de- 
pendent on the glycosylation of Asn 30. The glycosylation 
of Asn 30 might cause a conformational change, early in 
the folding process of CD3-,/, which is required for efficient 
glycosylation of Asn 70. Experiments performed with tuni- 
camycin showed that the non-glycosylated CD38, in con- 
trast to the other TCR chains, was not coprecipitated with 
CD3e. This indicated a role of CD38 glycosylation in TCR 
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chains or indirectly by influencing the structure of CD3~. 
Alternatively,  an  unknown  protein  involved  in  CD3~e 
dimer formation could be affected. The N-linked glycosy- 
lation sites of CD3~ are located differently than the glyco- 
sylation sites of CD3~/  (Fig.  1 A). In CD3~ three (mouse 
and rat) or two (human and sheep) glycosylation sites are 
found. In contrast to CD3~/these sites show a high degree 
of conservation.  Interestingly, two glycosylation sites are 
located just carboxy-terminal of the cysteines responsible 
for the intramolecular disulfide bond between the B-strands 
B and F. The first site is conserved among all four species 
whereas  the  second site is conserved among CD3~ from 
human, mouse, and rat (Fig. 1 A). The 13-strands  B and F 
are the most conserved regions in members of the Ig su- 
perfamily and it is likely that attachment of oligosaccha- 
ride in the center of these strands, next to the most con- 
served amino acid in  all members of the  Ig superfamily, 
may have an important influence on the conformation of 
CD3~. Further studies are in progress to study the role of 
N-linked glycosylation in TCR assembly. 
The Transmembrane Domain 
Cross-binding  experiments  have  demonstrated  a  close 
contact between CD3",/and TiB at the T cell surface (6, 31, 
52). Other experiments have indicated that this association 
could involve the TM charged residues of TiB and CD3~/ 
since point mutations of these amino acids abrogated TCR 
expression in T  cells (1) and CD3-Ti association in COS 
cells (23),  respectively. This is in agreement with our re- 
sults which demonstrated that the TM charged residue of 
CD3"y is involved in  TCR  assembly in  T  cells,  probably 
through  a direct interaction,  in the form of a  salt bridge, 
with the basic TM residue in TiB. Mutations of Glu 100 in 
the TM domain of CD3~,  demonstrated that  Glu or Gln 
was required for complete assembly and expression of the 
TCR. If Leu or Lys substituted for Glu 100 the TCR was 
not expressed at the cell surface. The presence of CD3~ in 
the anti-CD3~/precipitate and CD33, in the anti-CD3e pre- 
cipitate demonstrated that CD3~e dimers were formed in 
JGN-y-E100L cells. However, in these cells the TiB and the 
TietB  bands  were  markedly  decreased  in  the  anti-CD3"y 
precipitate  as compared to JGN-y-WT cells.  The  lack  of 
CD3~/  in  the  F101.01  precipitate  further  showed  that 
CD3~ did not associate with Tic~B in contrast to CD3~/in 
JGN~/-WT cells.  This  demonstrated  that  Glu  100  in  the 
TM  domain  of CD3~  is  not  involved in  the  association 
with the CD3e chain but is required for the association be- 
tween CD3~/e  dimers and TictB  dimers probably through 
binding to TiB. Changing Glu to Gin did not abolish TCR 
assembly and expression. Since Gin both chemically and 
physically resembles Glu this indicated  that the common 
properties  of  these  amino  acids  in  forming  hydrogen 
bonds or salt bridges are directly involved in TCR assem- 
bly. Such a hydrogen bond or salt bridge should be abro- 
gated if Glu 100 was changed to a hydrogen donor such as 
Lys or to a nonpolar amino acid such as Leu. The lack of 
TCR surface expression in  the JGN~-E100K and JGN~/- 
E100L transfectants supported this hypothesis. 
It seems likely that the TM charged amino acids of the 
TCR subunits have at least two roles: they are involved in 
TCR assembly in the ER by stabilizing the interaction be- 
tween the TCR chains and they are involved in regulation 
of the assembly process by inducing degradation of TCR 
chains that are in excess or TCR chains which, for some 
reason, are not able to function properly in the assembly 
process. The observation that the bands corresponding to 
partially glycosylated CD33~ and CD3~ were more intense 
in JGN'v-E100Q cells than  in JGN~/-WT cells could sug- 
gest that  the E100Q  mutation had a  stabilizing effect on 
CD3~/. 
The presence of nine charged amino acids in the trans- 
membrane region  of the TCR complex is puzzling since 
this gives a net charge of -3 provided that the TCR only 
contains one TietB dimer. Whether the TCR contains one 
or two Tic~[3 dimers is not fully known.  However, recent 
experiments have indicated that only one TiaB dimer is in- 
cluded in each TCR (24,  34,  46, 47). The BCR has a net 
charge of -4  and the Fc receptors, Fc~/RIIIA and Fc~RI, 
each have a net charge of -3 (40). The reason for this lack 
of equilibration of the TM region of the TCR, BCR, and 
FcR is not known, but it could be suggested that these re- 
ceptors are equilibrated by the presence of a yet unknown 
membrane protein(s). Recently it has been found that the 
murine  BCR  (mlgD)  is  associated  with  two  proteins, 
BAP29  and  BAP31,  which  could  equilibrate  the  trans- 
membrane region of the BCR complex (29). 
The Cytoplasmic Domain 
It has previously been demonstrated that deletion of the 
CY domain of either CD3e (51), CD3~ (7), or 4(57) does 
not  prevent assembly and  cell  surface  expression  of the 
TCR. In the present paper we showed that the CY domain 
of CD3-y is not required for TCR assembly and expression. 
These  observations support  the  hypothesis  that  whereas 
the EC and TM domains of the TCR are required for TCR 
assembly, expression,  and  recognition,  the  CY  domains 
are mainly responsible for signal transduction (38, 56, 57) 
and internalization of the TCR (16). 
In  conclusion,  based  on  the  results  from  the  present 
studies on TCR assembly in T cells we have demonstrated 
that (a) the association between CD3~/and CD3~ requires 
specific interaction sites in the EC domain of CD3~/but is 
independent of the charged amino acids in the TM domain 
of CD3% (b) the association between CD3~/and TiB re- 
quires the charged amino acid in the TM domain of CD3~ 
(Glu) or an amino acid with similar chemical and physical 
properties  (Gln),  and  (c)  the  association between  CD3~, 
and Tia[3 is influenced by the ability of CD3~/to assemble 
with Til3 and to a lesser degree with CD3~ indicating a hi- 
erarchy in  the TCR assembly process. Finally, glycosyla- 
tion of CD3-y  does not seem to influence  the stability of 
CD3~/or the assembly of the TCR. 
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